Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Income from Continuing Operations (2016 - 2025)

Heron Therapeutics' Income from Continuing Operations history spans 14 years, with the latest figure at 38000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 99.09% year-over-year to 38000.0; the TTM value through Dec 2025 reached 2538000.0, up 77.98%, while the annual FY2025 figure was 10195000.0, 27.23% up from the prior year.
  • Income from Continuing Operations reached 38000.0 in Q4 2025 per HRTX's latest filing, up from 4093000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 4173000.0 in Q4 2024 to a low of 62923000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 25858350.0, with a median of 22642000.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 165.74% in 2025 against a maximum downside of 99.09% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 53537000.0 in 2021, then soared by 61.98% to 20355000.0 in 2022, then skyrocketed by 49.79% to 10220000.0 in 2023, then surged by 140.83% to 4173000.0 in 2024, then crashed by 99.09% to 38000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Income from Continuing Operations are 38000.0 (Q4 2025), 4093000.0 (Q3 2025), and 1637000.0 (Q2 2025).